Ketamine can be used to manage treatment-resistant depression but researchers warn it should be done so sparingly.
Dr Ben Beaglehole.
In an editorial in this week’s New Zealand Medical Journal, Dr Ben Beaglehole, Associate Professor James Foulds and Professor Roger Mulder, all of the University of Otago, Christchurch, examine the use of ketamine to treat mental illness in New Zealand and how this is evolving.
They believe greater access to ketamine to manage treatment-resistant depression is beneficial, but do not support a “large-scale rapid increase” in ketamine use.
In New Zealand, ketamine is mainly used in research settings although there is limited use by publicly-funded specialty services. Recently, treatment has been offered by private providers.
Studies have shown ketamine is associated with large short-term improvements in depression symptoms, but can lead to high rates of relapse when treatment ends.
Managing these relapses will be a challenge for clinicians, Dr Beaglehole says.
“Additionally, there are concerns about the abuse potential of ketamine and other adverse factors including bladder issues and possible memory side effects.”
While most ketamine used recreationally is produced offshore, lessons learned from other medications indicate there may be some misuse and diversion of prescribed ketamine for illicit use.
“Patients who undergo this treatment will need to be carefully selected and closely monitored for adverse outcomes.
“The potential offered by ketamine is exciting but history suggests tempering our enthusiasm given lessons learned from other exciting treatments in our past.”
The Royal Australian and New Zealand College of Psychiatrists recommends restricting use to treatment-resistant depression (outside of research settings) and ensuring its use only occurs in services where clinicians are familiar with the drug and support structures are in place.
Dr Beaglehole says ketamine is best initiated by specialty services for the primary indication of treatment-resistant depression, although careful attention to equity of access is required.
Publication details:
The rise (and possible fall) of ketamine treatment in New Zealand
Ben Beaglehole, James Foulds, Roger Mulder
New Zealand Medical Journal (Friday 25 August 2023 edition)
For more information please contact:
Dr Ben Beaglehole
Senior lecturer
Department of Psychological Medicine
University of Otago, Christchurch
Email ben.beaglehole@otago.ac.nz
Jessica Wilson
Adviser Media Engagement
University of Otago
Mob +64 21 279 5016
Email jessica.wilson@otago.ac.nz